JSJonathan T. Skare

Jonathan T. Skare

*This is an algorithmically generated author record based on publicly available information.

Jonathan T. Skare has a total of 109 co-authors. Here are the top co-authors by number of shared publications:

  • Brandon Lee Garcia

    Kansas State University

    10 shared publications
  • Jenny A. Hyde

    Department of Microbial Pathogenesis and Immunology, Texas A&M University

    10 shared publications
  • Jerome P. Trzeciakowski

    Department of Systems Biology and Translational Medicine, Texas A&M Health Science Center, College Station, TX 77843, USA

    5 shared publications
  • Alexandra D. Powell-Pierce

    Affiliation Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University, Bryan/College Station, Texas, United States of America

    4 shared publications
  • Beau Wager

    Department of Molecular Biology and Microbiology, Tufts University, School of Medicine, Boston, Massachusetts, United States of America

    4 shared publications
  • Charles E. Booth

    Affiliation Department of Microbiology and Immunology, Brody school of Medicine, East Carolina University, Greenville, North Carolina, United States of America

    4 shared publications

Latest Publications

  • Open Access

    Borrelia burgdorferi infection-enhanced Ixodes scapularis serpins S12c5 and S13c5, target MASP1/3 to inhibit MBL-pathway complement activation and promote spirochete survival

    by Emily Bencosme-Cuevas, Tae Kim, Thu-Thuy Nguyen, Moiz A Ansari, Shahbaz M Khan, Payton G Smith, Kyla R Herr, Yungui Guo, William H. Witola, Jon T. Skare, et al.

    Tick serine protease inhibitors (serpins) are critical for tick feeding success and pathogen transmission. We previously demonstrated that two unique serpins, S12c5 and S13c5, are tandemly duplicated on Ixodes scapularis chromosome 5 and are injected into the host at heightened levels during feeding by Borrelia burgdorferi (Bb)-infected nymphs. Here, we characterize the biochemical properties and immunomodulatory functions of these serpins and investigate their roles in promoting Bb transmission. Despite their genomic proximity, S12c5 and S13c5 share less than 20% overall amino acid identity and differ critically at their reactive center loop (RCL) P1 site, which determines substrate specificity: S13c5 contains a basic arginine residue, while S12c5 contains a polar serine residue. Consistent with these differences, recombinant S13c5 efficiently inhibited innate immune proteases including fXa, plasmin, and trypsin IV (SI: 2.5, 1.9, and 1.0; ka: 8.56 × 10³, 3.97 × 10 5 , and 1.08 × 10 5 M −1 s −1 , respectively), and consequently delayed plasma clotting via the common pathway, whereas rS12c5 did not inhibit these proteases. However, despite molecular modeling predicting stronger interactions between S13c5 and complement proteases, both serpins inhibited MBL-pathway complement activation by targeting MASP1/3. Deletion of the RCL domain abolished this inhibitory activity, confirming both proteins function as typical inhibitory serpins. Functionally, rS13c5 enhanced Bb colonization in C3H mouse organs. Interestingly, immune response assays revealed a trade-off: S13c5, despite its broader inhibitory activity, was less immunogenic than S12c5. Collectively, these findings establish S12c5 and S13c5 as Bb transmission factors that promote spirochete survival through disruption of host innate immunity.

  • Open Access

    The Borreliella burgdorferi BosR-associated small non-coding RNA BasA regulates virulence

    by Brittany L. Shapiro, Prashant Jaiswal, Lisa J. Funkhouser-Jones, Sourav Roy, Taylor J. Van Gundy, Jeremy M. Bono, Meghan C. Lybecker, Brandon L. Garcia, Jenny A. Hyde, Jon T. Skare

    Post-transcriptional regulation is an adaptive response used by living systems to alter protein levels independently of transcription initiation. In bacteria, one mechanism of post-transcriptional regulation involves the binding of small, non-coding RNAs (sRNAs) to target mRNAs to regulate their translation into protein. This regulation generally includes an RNA-binding protein that facilitates the sRNA::mRNA interaction. In the etiological agent of Lyme disease, Borreliella burgdorferi , over 400 temperature-dependent sRNAs have been identified. Here, we characterized the sRNA SR0735, which is upregulated at 37°C (characteristic of mammalian infection). Transcriptomic and proteomic analyses revealed that deleting SR0735 in B. burgdorferi resulted in reduced production of virulence-associated, RpoS-dependent proteins due to a reduction of RpoS and its upstream regulator BosR. We thus renamed SR0735 as BasA for B osR- a ssociated s RNA locus A . Consistent with previous studies that identified BosR as an RNA-binding protein, we demonstrate here that BosR can bind BasA in vitro . Importantly, the loss of BasA significantly attenuated B. burgdorferi infectivity during murine infection, which is consistent with the reduced levels of BosR and RpoS observed. The emerging model suggests that BasA is required for optimal levels of BosR protein through the post-transcriptional regulation of bosR mRNA, which, in turn, promotes the production of RpoS and its downstream genes required for mammalian infectivity and pathogenesis.


  • Open Access

    BBK32 attenuates antibody-dependent complement-mediated killing of infectious Borreliella burgdorferi isolates

    by Alexandra D. Powell-Pierce, Charles E. Booth, Payton G. Smith, Brittany L. Shapiro, Shannon S. Allen, Brandon L. Garcia, Jon T. Skare

    Borreliella burgdorferi, the causative agent of Lyme disease, has evolved unique complement evasion proteins that promote its ability to establish and maintain infection in mammalian hosts. Among these is B. burgdorferi BBK32, a multifunctional surface lipoprotein that binds extracellular matrix (ECM) components, including fibronectin (Fn). In addition to its ECM-binding functions, BBK32 binds to C1r, the initiator protease of the classical pathway of complement, and protects B. burgdorferi from complement-mediated killing following exposure to normal human serum. The disparate functions of BBK32 in adhesion and complement evasion have previously been studied in isolation. Herein we demonstrate that full-length BBK32 binds both Fn and C1 concurrently, indicating that binding of these macromolecules do not sterically hinder their simultaneous interaction. Given the link of antibody dependence to the classical pathway, we tested how the presence of BBK32 would protect infectious B. burgdorferi from borrelial-specific antibodies in a complement-dependent manner. BBK32 provided protection against complement activation in the presence of borrelial-specific antibodies in vitro. We also demonstrated, using both flow cytometry and fluorescence microscopy, that BBK32 results in the reduction of C4 deposition on the surface of borrelial cells. This work demonstrates that BBK32 can simultaneously bind to both C1r and Fn and contributes to the broader understanding of the ability of B. burgdorferi to evade antibody-dependent complement-mediated killing. These observations are significant as they suggest that BBK32 plays a dual role in adhesion and dissemination in infectious B. burgdorferi, as well as immune evasion activities, which ostensibly promotes its pathogenic potential.


  • Open Access

    The dual activity of BBK32: Implications for simultaneous inhibition of borrelial-specific antibody-dependent complement activation and fibronectin binding

    by Alexandra D. Powell-Pierce, Charles E. Booth, Payton Smith, Brittany L. Shapiro, Shannon S. Allen, Brandon L. Garcia, Jon T. Skare

    Complement inhibition is exploited by extracellular pathogens to combat clearance. Borreliella burgdorferi , the causative agent of Lyme disease, harnesses complement evasion techniques to establish and maintain infection in mammalian hosts. B. burgdorferi encodes bbk32 , a surface lipoprotein that binds extracellular matrix (ECM) components, specifically glycosoaminoglycans (GAGs) and fibronectin (Fn) within its amino terminus. In addition to its ECM-binding functions, the carboxy terminal half of BBK32 binds to the C1r protease and prevents complement activation. This classical complement inhibitory activity protects B. burgdorferi from complement-mediated killing following the addition of normal human serum. Herein we demonstrate that full length BBK32 binds both Fn and C1 concurrently, indicating that binding of these macromolecules do not sterically hinder their simultaneous interaction. Given the link of antibody dependence to the classical pathway, we tested how the presence of BBK32 would protect B. burgdorferi from antibody mediated, complement dependent killing. The presence of BBK32 provided protection against borrelial-specific antibody binding and concomitant complement activation in vitro . We also demonstrated, using both fluorescence microscopy and flow cytometry, that the presence of BBK32 was required for reduced C4 deposition on the surface of borrelial cells. This work demonstrates the potential for BBK32 to simultaneously bind to both C1r and Fn and contributes to the broader understanding of the ability of B. burgdorferi to evade antibody-dependent complement-mediated killing. We contend that these observations ostensibly provide B. burgdorferi with coincident dissemination and immune evasion activities needed for optimal survival during infection. AUTHOR SUMMARY: Lyme disease, caused by Borreliella burgdorferi and other related species, is the most common arthropod-borne infection in the United States. As an extracellular pathogen, B. burgdorferi is exposed to the complement system--a soluble proteolytic cascade that clears invaders. Complement is defined by three pathways known as the alternative, lectin, and classical. The classical complement cascade is activated by the binding of antibodies to a foreign or damaged cell. For B. burgdorferi , the BBK32 surface protein is known to mute the classical pathway by binding and inhibiting the initiating protease C1r. However, no studies have addressed how BBK32 protects infectious B. burgdorferi from borrelial-specific antibody binding and clearance. Here we show that native BBK32 protects infectious B. burgdorferi from antibody-dependent, complement mediated killing. Given BBK32s other activity—namely its known adherence to fibronectin—we were interested to test if BBK32 could bind the C1 complex, which contains C1r, together with fibronectin. Our results suggest that these complex macromolecules can bind BBK32 simultaneously. These observations suggest that the dual activity of BBK32, namely fibronectin binding and C1r inhibition, are not mutually exclusive and contribute to B. burgdorferi ’s ability to establish infection and evade antibody-based host clearance, respectively.

  • Open Access

    Conformational dynamics of complement protease C1r inhibitor proteins from Lyme disease– and relapsing fever–causing spirochetes

    by Sourav Roy, Charles E. Booth, Alexandra D. Powell-Pierce, Anna M. Schulz, Jon T. Skare, Brandon L. Garcia


  • Open Access

    “Conformational dynamics of C1r inhibitor proteins from Lyme disease and relapsing fever spirochetes”

    by Sourav Roy, Charles E. Booth, Alexandra D. Powell-Pierce, Anna M. Schulz, Jon T. Skare, Brandon L. Garcia

    Borrelial pathogens are vector-borne etiological agents of Lyme disease, relapsing fever, and Borrelia miyamotoi disease. These spirochetes each encode several surface-localized lipoproteins that bind to components of the human complement system. BBK32 is an example of a borrelial lipoprotein that protects the Lyme disease spirochete from complement-mediated attack. The complement inhibitory activity of BBK32 arises from an alpha helical C-terminal domain that interacts directly with the initiating protease of the classical pathway, C1r. Borrelia miyamotoi spirochetes encode BBK32 orthologs termed FbpA and FbpB, and these proteins also inhibit C1r, albeit via distinct recognition mechanisms. The C1r-inhibitory activities of a third ortholog termed FbpC, which is found exclusively in relapsing fever spirochetes, remains unknown. Here we report the crystal structure of the C-terminal domain of B. hermsii FbpC to a limiting resolution of 1.5 Å. Surface plasmon resonance studies and assays of complement function demonstrate that FbpC retains potent BBK32-like anti-complement activities. Based on the structure of FbpC, we hypothesized that conformational dynamics of the complement inhibitory domains of borrelial C1r inhibitors may differ. To test this, we utilized the crystal structures of the C-terminal domains of BBK32, FbpA, FbpB, and FbpC to carry out 1 µs molecular dynamics simulations, which revealed borrelial C1r inhibitors adopt energetically favored open and closed states defined by two functionally critical regions. This study advances our understanding of how protein dynamics contribute to the function of bacterial immune evasion proteins and reveals a surprising plasticity in the structures of borrelial C1r inhibitors.

  • Minimal role for the alternative pathway in complement activation by HIT immune complexes

    by Ayiesha P. Barnes, Sanjay Khandelwal, Simone Sartoretto, Sooho Myoung, Samuel J. Francis, Grace M. Lee, Lubica Rauova, Douglas B. Cines, Jon T. Skare, Charles E. Booth, et al.


  • Open Access

    Borrelia miyamotoi FbpA and FbpB Are Immunomodulatory Outer Surface Lipoproteins With Distinct Structures and Functions

    by Charles E. Booth, Alexandra D. Powell-Pierce, Jon T. Skare, Brandon L. Garcia

    Pathogens that traffic in the blood of their hosts must employ mechanisms to evade the host innate immune system, including the complement cascade. The Lyme disease spirochete,Borreliella burgdorferi, has evolved numerous outer membrane lipoproteins that interact directly with host proteins. Compared to Lyme disease-associated spirochetes, relatively little is known about how an emerging tick-borne spirochetal pathogen,Borrelia miyamotoi, utilizes surface lipoproteins to interact with a human host.B. burgdorferiexpresses the multifunctional lipoprotein, BBK32, that inhibits the classical pathway of complement through interaction with the initiating protease C1r, and also interacts with fibronectin using a separate intrinsically disordered domain.B. miyamotoiencodes two separatebbk32orthologs denotedfbpAandfbpB; however, the activities of these proteins are unknown. Here, we show thatB. miyamotoiFbpA binds human fibronectin in a manner similar toB. burgdorferiBBK32, whereas FbpB does not. FbpA and FbpB both bind human complement C1r and protect a serum-sensitiveB. burgdorferistrain from complement-mediated killing, but surprisingly, differ in their ability to recognize activated C1r versus zymogen states of C1r. To better understand the observed differences in C1r recognition and inhibition properties, high-resolution X-ray crystallography structures were solved of the C1r-binding regions ofB. miyamotoiFbpA and FbpB at 1.9Å and 2.1Å, respectively. Collectively, these data suggest that FbpA and FbpB have partially overlapping functions but are functionally and structurally distinct. The data presented herein enhances our overall understanding of how bloodborne pathogens interact with fibronectin and modulate the complement system.


  • Open Access

    A Structural Basis for Inhibition of the Complement Initiator Protease C1r by Lyme Disease Spirochetes

    by Ryan J. Garrigues, Alexandra D. Powell-Pierce, Michal Hammel, Jon T. Skare, Brandon L. Garcia

    Complement evasion is a hallmark of extracellular microbial pathogens such as Borrelia burgdorferi, the causative agent of Lyme disease. Lyme disease spirochetes express nearly a dozen outer surface lipoproteins that bind complement components and interfere with their native activities. Among these, BBK32 is unique in its selective inhibition of the classical pathway. BBK32 blocks activation of this pathway by selectively binding and inhibiting the C1r serine protease of the first component of complement, C1. To understand the structural basis for BBK32-mediated C1r inhibition, we performed crystallography and size-exclusion chromatography–coupled small angle X-ray scattering experiments, which revealed a molecular model of BBK32-C in complex with activated human C1r. Structure-guided site-directed mutagenesis was combined with surface plasmon resonance binding experiments and assays of complement function to validate the predicted molecular interface. Analysis of the structures shows that BBK32 inhibits activated forms of C1r by occluding substrate interaction subsites (i.e., S1 and S1’) and reveals a surprising role for C1r B loop–interacting residues for full inhibitory activity of BBK32. The studies reported in this article provide for the first time (to our knowledge) a structural basis for classical pathway–specific inhibition by a human pathogen.


  • Open Access

    A structural basis for inhibition of the complement initiator protease C1r by Lyme disease spirochetes

    by Ryan J. Garrigues, Alexandra D. Powell Pierce, Michal Hammel, Jon T. Skare, Brandon L. Garcia

    Complement evasion is a hallmark of extracellular microbial pathogens such as Borreliella burgdorferi , the causative agent of Lyme disease. Lyme disease spirochetes express nearly a dozen outer surface lipoproteins that bind complement components and interfere with their native activities. Among these, BBK32 is unique in its selective inhibition of the classical pathway. BBK32 blocks activation of this pathway by selectively binding and inhibiting the C1r serine protease of first component of complement, C1. To understand the structural basis for BBK32-mediated C1r inhibition, we performed co-crystallography and size exclusion chromatography-coupled small angle x-ray scattering experiments, which revealed a molecular model of BBK32-C in complex with activated human C1r. Structure-guided site-directed mutagenesis was combined with surface plasmon resonance binding experiments and assays of complement function to validate the predicted molecular interface. The studies reported here, for the first time, provide a structural basis for classical pathway-specific inhibition by a human pathogen.